Back

Search results

Found 1822 results. Displaying page 43 of 122

  1. 5 July 2022

    Exemption Notice - Financial Markets Conduct Futurity Investment Group Limited

    The Financial Markets Conduct (Futurity Investment Group Limited) Exemption Notice 2022 exempts Futurity Investment Group Limited (the manager), as manager of Futurity managed investment schemes in New Zealand, principally from section 156(1) of the Financial Markets Conduct Act 2013 (the Act) subject to certain conditions.

  2. 5 July 2022

    Exemption Notice - Financial Markets Conduct Goodman Group

    The Financial Markets Conduct (Goodman Group) Exemption Notice 2022 provides relief for a five year period in relation to the offer of stapled securities to employees in New Zealand under an employee incentive scheme.

  4. 5 July 2022

    FMA DIMS SC2 consultation feedback form

    Feedback form for consultation paper: Proposed variation to Standard Condition 2 of Standard Conditions for DIMS licences – Incidental financial advice

  6. 5 July 2022

    FMA DIMS SC2 consultation paper

    Consultation paper: Proposed variation to Standard Condition 2 of Standard Conditions for DIMS licences – Incidental financial advice

  9. 28 June 2022

    NZX Obligations Review 2022

    Findings from the FMA's review of how well NZX is meeting its licensed market operator obligations, for the period 1 January to 31 December 2021.

  12. 16 June 2022

    Investor Confidence Report 2022

    The Investor confidence Research report 2022 measures attitudes towards and investment in New Zealand’s financial markets.

  14. 14 June 2022

    Cigna and OnePath Life - Enforceable Undertaking

    OnePath Life (NZ) Limited and Cigna Life Insurance New Zealand Limited will jointly pay $180,000 to the FMA after admitting liability for breaching the fair dealing provisions of the Financial Markets Conduct Act 2013 (FMCA). 14 June 2022

  15. 1 June 2022

    Exemption Notice - Haleon plc

    The Financial Markets Conduct (Haleon plc) Exemption Notice 2022 exempts GlaxoSmithKline plc (GSK) and Haleon plc (Haleon) from the obligations in Part 3 (Disclosure of offers of financial products) of the Financial Markets Conduct Act 2013.